Urinary desmosine: A biomarker of structural lung injury during CF pulmonary exacerbation

Pediatric Pulmonology

Volumn 47, Issue 9, 2012, Pages 856-863

  Laguna, Theresa A ^a   Wagner, Brandie D ^b   Starcher, Barry ^c   Luckey Tarro, Heidi K ^d   Mann, Shelley A ^d   Sagel, Scott D ^d   Accurso, Frank J ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Global Health and Health Disparities   (United States)

^c UNIVERSITY OF TEXAS AT TYLER   (United States)

^d Children's Hospital Colorado   (United States)

Author keywords

airway; elastin breakdown; inflammation; matrix

Indexed keywords

AMINOGLYCOSIDE; ANTIFUNGAL AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBAPENEM; CREATININE; DESMOSINE; INTERLEUKIN 8; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BLOOD SAMPLING; CHILD; CREATININE URINE LEVEL; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; KIDNEY CONCENTRATING CAPACITY; LUNG FUNCTION; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RELATIVE DENSITY; SPUTUM ANALYSIS; URINALYSIS; URINE LEVEL;

AIRWAY REMODELING; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; CYSTIC FIBROSIS; DESMOSINE; DISEASE PROGRESSION; ELASTIN; FEMALE; HUMANS; INTERLEUKIN-8; LUNG INJURY; MALE; PNEUMONIA; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS;

EID: 84865101337     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22525     Document Type: Article

References (46)

1. Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR,. Cystic fibrosis. Cystic fibrosis in the metabolic and molecular basis of inherited disease, 7th edition. New York: McGraw-Hill; 2001. pp 521-588.
2. Chmiel JF, Berger M, Konstan MW,. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002; 23: 5-27.
3. Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski JF Jr, Dearborn DG,. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 1985; 132: 529-535.
4. Starcher BC,. Lung elastin matrix. Chest 2000; 117: 229S-234S.
5. Starcher BC, Goldstein RA,. Studies on the absorption of desmosine and isodesmosine. J Lab Clin Med 1979; 94: 848-852.
6. Stone PJ, Lucey EC, Snider GL, Franzblau C,. Effect of diet on urinary excretion of desmosine and hydroxylysyl pyridinoline. Am J Respir Crit Care Med 1994; 149: 174-177.
7. Luisetti M, Ma S, Iadarola P, Stone PJ, Viglio S, Casado B, Lin YY, Snider GL, Turino GM,. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 2008; 32: 1146-1157.
8. Ferkol T, Rosenfeld M, Milla CE,. Cystic fibrosis pulmonary exacerbations. Pediatrics 2006; 148: 259-264.
9. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B,. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001; 139: 359-365.
10. Smith AL, Redding G, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Rubio T,. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988; 112: 547-554.
11. Ordonez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML,. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 1471-1475.
12. Downey DG, Brockbank S, Martin SL, Ennis M, Elborn JS,. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol 2007; 42: 729-735.
13. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH,. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182: 627-632.
14. Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH,. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010; 45: 127-134.
15. Stone PJ, Konstan MW, Berger M, Dorkin HL, Franzblau C, Snider GL,. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med 1995; 152: 157-162.
16. Starcher B, Green M, Scott M,. Measurement of urinary desmosine as an indicator of acute pulmonary disease. Respiration 1995; 62: 252-257.
17. Bode DC, Pagani ED, Cumiskey WR, von Roemeling R, Hamel L, Silver PJ,. Comparison of urinary desmosine excretion in patients with chronic obstructive pulmonary disease or cystic fibrosis. Pulm Pharmacol Ther 2000; 13: 175-180.
18. Laguna TA, Wagner BD, Luckey HK, Mann SA, Sagel SD, Regelmann W, Accurso FJ,. Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis. Chest 2009; 136: 1561-1568.
19. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW III., Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: cystic fibrosis foundation consensus report. J Pediatr 2008; 153: S4-S14.
20. Winfield KR, Gard S, Kent GN, Sly PD, Brennan S,. Assay for urinary desmosines in a healthy pre-pubertal population using an improved extraction technique. Ann Clin Biochem 2006; 43: 146-152.
21. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ,. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001; 164: 1425-1431.
22. Starcher B,. A ninhydrin-based assay to quantitate the total protein content of tissue samples. Anal Biochem 2001; 292: 125-129.
23. Starcher B, Conrad M,. A role for neutrophil elastase in the progression of solar elastosis. Connect Tissue Res 1995; 31: 133-140.
24. King GS, Mohan VS, Starcher BC,. Radioimmunoassay for desmosine. Connect Tissue Res 1980; 7: 263-267.
25. Gaines LG, Fent KW, Flack SL, Thomasen JM, Ball LM, Zhou H, Whittaker SG, Nylander-French LA,. Effect of creatinine and specific gravity normalization on urinary biomarker 1,6-hexamethylene diamine. J Environ Monit 2010; 12: 591-599.
26. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202-1218.
27. Wagner BD, Accurso FJ, Laguna TA,. The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population. J Cyst Fibros 2010; 9: 212-216.
28. Liu Y, Schutz RW,. Statistical validity of using ratio variables in human kinetics research. Res Q Exerc Sport 2003; 74: 226-235.
29. Waikar SS, Sabbisetti VS, Bonventre JV,. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int 2010; 78: 486-494.
30. Thiebaut R, Jacqmin-Gadda H, Chene G, Leport C, Commenges D,. Bivariate linear mixed models using SAS proc MIXED. Comput Methods Programs Biomed 2002; 69: 249-256.
31. Goldstein RA, Starcher BC,. Urinary excretion of elastin peptides containing desmosin after intratracheal injection of elastase in hamsters. J Clin Invest 1978; 61: 1286-1290.
32. Janoff A, Chanana AD, Joel DD, Susskind H, Laurent P, Yu SY, Dearing R,. Evaluation of the urinary desmosine radioimmunoassay as a monitor of lung injury after endobronchial elastase instillation in sheep. Am Rev Respir Dis 1983; 128: 545-551.
33. Stone PJ, Bryan-Rhadfi J, Lucey EC, Ciccolella DE, Crombie G, Faris B, Snider GL, Franzblau C,. Measurement of urinary desmosine by isotope dilution and high performance liquid chromatography. correlation between elastase-induced air-space enlargement in the hamster and elevation of urinary desmosine. Am Rev Respir Dis 1991; 144: 284-290.
34. Downey DG, Martin SL, Dempster M, Moore JE, Keogan MT, Starcher B, Edgar J, Bilton D, Elborn JS,. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol 2007; 42: 216-220.
35. Harel S, Yu SY, Janoff A, Hurewitz A, Bergofsky EH,. Measurement of elastin degradation in vivo by desmosine radioimmunoassay. Bull Eur Physiopathol Respir 1980; 16: 75-82.
36. Stone PJ, Gottlieb DJ, O'Connor GT, Ciccolella DE, Breuer R, Bryan-Rhadfi J, Shaw HA, Franzblau C, Snider GL,. Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 952-959.
37. Gottlieb DJ, Stone PJ, Sparrow D, Gale ME, Weiss ST, Snider GL, O'Connor GT,. Urinary desmosine excretion in smokers with and without rapid decline of lung function: the normative aging study. Am J Respir Crit Care Med 1996; 154: 1290-1295.
38. Viglio S, Iadarola P, Lupi A, Trisolini R, Tinelli C, Balbi B, Grassi V, Worlitzsch D, Doring G, Meloni F, Meyer KC, Dowson L, Hill SL, Stockley RA, Luisetti M,. MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients. Eur Respir J 2000; 15: 1039-1045.
39. Ma S, Lin YY, Turino GM,. Measurements of desmosine and isodesmosine by mass spectrometry in COPD. Chest 2007; 131: 1363-1371.
40. Cocci F, Miniati M, Monti S, Cavarra E, Gambelli F, Battolla L, Lucattelli M, Lungarella G,. Urinary desmosine excretion is inversely correlated with the extent of emphysema in patients with chronic obstructive pulmonary disease. Int J Biochem Cell Biol 2002; 34: 594-604.
41. Fiorenza D, Viglio S, Lupi A, Baccheschi J, Tinelli C, Trisolini R, Iadarola R, Luisetti M, Snider GL,. Urinary desmosine excretion in acute exacerbations of COPD: a preliminary report. Respir Med 2002; 96: 110-114.
42. Sagel SD,. Noninvasive biomarkers of airway inflammation in cystic fibrosis. Curr Opin Pulm Med 2003; 9: 516-521.
43. Davies SF, Offord KP, Brown MG, Campe H, Niewoehner D,. Urine desmosine is unrelated to cigarette smoking or to spirometric function. Am Rev Respir Dis 1983; 128: 473-475.
44. McClintock DE, Starcher B, Eisner MD, Thompson BT, Hayden DL, Church GD, Matthay MA, National Heart, Lung, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Higher urine desmosine levels are associated with mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 2006; 291: L566-L571.
45. Gerszten RE, Accurso F, Bernard GR, Caprioli RM, Klee EW, Klee GG, Kullo I, Laguna TA, Roth FP, Sabatine M, Srinivas P, Wang TJ, Ware LB,. Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI clinical proteomics programs. Am J Physiol Lung Cell Mol Physiol 2008; 295: L16-L22.
46. Heavner DL, Morgan WT, Sears SB, Richardson JD, Byrd GD, Ogden MW,. Effect of creatinine and specific gravity normalization techniques on xenobiotic biomarkers in smokers' spot and 24-h urines. J Pharm Biomed Anal 2006; 40: 928-942.